Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Jun 7, 2022

FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis

Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Jun 7, 2022

Sanofi unveils new 900,000-square-foot campus at Cambridge Crossing
Jun 3, 2022

Provention Bio Announces the Grant of Inducement Awards
Jun 3, 2022

Provention Bio to Present at the Jefferies Global Healthcare Conference
Jun 3, 2022

Provention Bio Announces Update to Board of Directors

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.